Publication: 4134

Publication: 4134

Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.

PubMed

DOI

Google Scholar

Citation:: Am J Hematol vol 99 (7) 1257-68

Year:: 2024
Type:: Manuscript
Funding:: AFT
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 13

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: Myeloma
Sec. Committees:

Pharmas:: Janssen Oncology
Grants:

Corr. Author:
Authors:: Rebecca Silbermann Jacob Laubach Jonathan L Kaufman Douglas W Sborov Brandi Reeves Cesar Rodriguez Ajai Chari Luciano J Costa Larry D Anderson Nitya Nathwani Nina Shah Naresh Bumma Sarah A Holstein Caitlin Costello Andrzej Jakubowiak Robert Z Orlowski Kenneth H Shain Andrew J Cowan Katharine S Gries Huiling Pei Annelore Cortoos Sharmila Patel Thomas S Lin Peter M Voorhees Saad Z Usmani Paul G Richardson

Networks:: CA043, CA249, CA824, FL065, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-NY016, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, NE003, NEWMEXICO, NY021, OR013

Study: AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: